BioSyent Inc. (CVE:RX - Get Free Report) shares passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of C$11.36 and traded as high as C$11.45. BioSyent shares last traded at C$11.00, with a volume of 6,223 shares trading hands.
BioSyent Stock Performance
The stock has a 50 day moving average of C$11.36 and a two-hundred day moving average of C$10.75. The stock has a market capitalization of C$129.34 million, a PE ratio of 18.60 and a beta of 0.93. The company has a debt-to-equity ratio of 3.19, a current ratio of 6.13 and a quick ratio of 6.91.
Insiders Place Their Bets
In other BioSyent news, insider FAX Capital Corp. sold 230,800 shares of the business's stock in a transaction on Friday, November 22nd. The stock was sold at an average price of C$11.12, for a total transaction of C$2,566,496.00. Also, Senior Officer Robert Joseph March sold 4,775 shares of the company's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of C$11.65, for a total value of C$55,628.75. In the last ninety days, insiders have sold 349,144 shares of company stock worth $3,903,370. Corporate insiders own 33.65% of the company's stock.
About BioSyent
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
See Also
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
